Indrayani Biotech Limited (BOM:526445)
India · Delayed Price · Currency is INR 10.24
+0.16 (1.59%)
At close: Oct 6, 2026
Indrayani Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,464 | 1,378 | 1,302 | 1,662 | 1,629 | 615.72 |
Other Revenue | 5.35 | 0 | 0 | - | 0.02 | 0.11 |
| 1,470 | 1,378 | 1,302 | 1,662 | 1,629 | 615.82 | |
Revenue Growth | 14.59% | 5.84% | -21.66% | 2.02% | 164.57% | 190.60% |
Cost of Revenue | 1,054 | 940.73 | 827.72 | 989.28 | 1,039 | 414.11 |
Gross Profit | 416.07 | 437.58 | 474.56 | 672.98 | 590.2 | 201.72 |
Selling, General & Admin | 143.93 | 141.62 | 204.68 | 258.36 | 252.87 | 107.75 |
Other Operating Expenses | 177.63 | 199.67 | 207.27 | 170.03 | 157.06 | 25.2 |
Operating Expenses | 366.94 | 384.3 | 445.63 | 466.39 | 443.41 | 139.54 |
Operating Income | 49.13 | 53.29 | 28.94 | 206.58 | 146.79 | 62.17 |
Interest Expense | -88.05 | -96.01 | -117.63 | -98.83 | -49.99 | -18.26 |
Interest & Investment Income | - | - | - | 1.57 | 26.09 | 1.14 |
Other Non Operating Income (Expenses) | 45.72 | 45.72 | 31.26 | 0.42 | 4.65 | -0.54 |
EBT Excluding Unusual Items | 6.8 | 3 | -57.44 | 109.74 | 127.54 | 44.52 |
Asset Writedown | - | - | - | - | -5 | - |
Other Unusual Items | - | - | - | - | 0.52 | - |
Pretax Income | 6.8 | 3 | -57.44 | 109.74 | 123.06 | 44.52 |
Income Tax Expense | -18.64 | -18.6 | 3.64 | 5.52 | 3.75 | 0.12 |
Earnings From Continuing Operations | 25.44 | 21.6 | -61.08 | 104.22 | 119.31 | 44.4 |
Minority Interest in Earnings | -17.9 | -17.9 | 45.51 | -40.58 | -31.94 | -0.46 |
Net Income | 7.54 | 3.7 | -15.57 | 63.65 | 87.37 | 43.93 |
Net Income to Common | 7.54 | 3.7 | -15.57 | 63.65 | 87.37 | 43.93 |
Net Income Growth | - | - | - | -27.15% | 98.87% | - |
Shares Outstanding (Basic) | 11 | 8 | 12 | 36 | 34 | 34 |
Shares Outstanding (Diluted) | 11 | 8 | 12 | 46 | 43 | 34 |
Shares Change | -79.58% | -33.10% | -74.68% | 4.74% | 27.02% | -3.86% |
EPS (Basic) | 0.71 | 0.48 | -1.35 | 1.75 | 2.55 | 1.28 |
EPS (Diluted) | 0.71 | 0.48 | -1.35 | 1.40 | 2.01 | 1.28 |
EPS Growth | - | - | - | -30.35% | 57.03% | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 237.49 | -81.17 | -468.41 | -53.4 | 29.22 |
Free Cash Flow Per Share | - | 30.78 | -7.04 | -10.29 | -1.23 | 0.85 |
Gross Margin | 28.31% | 31.75% | 36.44% | 40.49% | 36.22% | 32.76% |
Operating Margin | 3.34% | 3.87% | 2.22% | 12.43% | 9.01% | 10.10% |
Profit Margin | 0.51% | 0.27% | -1.20% | 3.83% | 5.36% | 7.13% |
Free Cash Flow Margin | - | 17.23% | -6.23% | -28.18% | -3.28% | 4.75% |
EBITDA | 94.47 | 96.3 | 62.62 | 244.64 | 180.26 | 68.77 |
EBITDA Margin | 6.43% | 6.99% | 4.81% | 14.72% | 11.06% | 11.17% |
D&A For EBITDA | 45.35 | 43.01 | 33.68 | 38.05 | 33.47 | 6.59 |
EBIT | 49.13 | 53.29 | 28.94 | 206.58 | 146.79 | 62.17 |
EBIT Margin | 3.34% | 3.87% | 2.22% | 12.43% | 9.01% | 10.10% |
Effective Tax Rate | - | - | - | 5.03% | 3.05% | 0.28% |
Revenue as Reported | 1,515 | 1,424 | 1,334 | 1,674 | 1,674 | 617.93 |
Advertising Expenses | - | - | - | 8.19 | 8.89 | 1.65 |